Table 1. Comparison of pretreatment... | American Society of Hematology

Table 1.

Comparison of pretreatment variables in training and validation patient cohorts

Pretreatment variable	Training cohort, n = 82	Validation cohort, n = 23	P
Median age, y (first and third quartiles)	62 (55, 69)	58.0 (40, 65)	.08‡
Median duration of RCTD, mo (first and third quartiles)	9.2 (3.0, 25.2)	13.0 (6.0, 30.0)	.43‡
DR15⁺ (%)	29/77 (38)	8/23 (35)	.80§
Hypocellular bone marrow (%)*	20/82 (24)	2/23 (9)	.10§
Less than 5% bone marrow blasts (%)	60/82 (73)	19/23 (83)	.35§
Normal cytogenetics (%)	53/82 (65)	15/21 (71)	.55§
Pancytopenia (%)†	38/82 (46)	8/23 (35)	.32§
PNH present by flow cytometric analysis (%)	8/77 (10)	5/23 (22)	.15§
Response to immunosuppression (%)	24/82 (29)	7/23 (30)	.91§

Pretreatment variable	Training cohort, n = 82	Validation cohort, n = 23	P
Median age, y (first and third quartiles)	62 (55, 69)	58.0 (40, 65)	.08‡
Median duration of RCTD, mo (first and third quartiles)	9.2 (3.0, 25.2)	13.0 (6.0, 30.0)	.43‡
DR15⁺ (%)	29/77 (38)	8/23 (35)	.80§
Hypocellular bone marrow (%)*	20/82 (24)	2/23 (9)	.10§
Less than 5% bone marrow blasts (%)	60/82 (73)	19/23 (83)	.35§
Normal cytogenetics (%)	53/82 (65)	15/21 (71)	.55§
Pancytopenia (%)†	38/82 (46)	8/23 (35)	.32§
PNH present by flow cytometric analysis (%)	8/77 (10)	5/23 (22)	.15§
Response to immunosuppression (%)	24/82 (29)	7/23 (30)	.91§

Cellularity less than 30%.

Platelets less than 50 × 10⁹/L, red cell transfusion dependence, and absolute neutrophils less than 500 × 10⁹/L.

Kruskal-Wallis test for medians.

χ² test.